plerixafor has been researched along with Glioma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ackermann, R; Alghamri, MS; Andjelkovic, AV; Apfelbaum, AA; Appelman, H; Banerjee, K; Barissi, M; Calinescu, A; Candolfi, M; Carney, S; Castro, MG; Comba, A; Edwards, MB; Faisal, SM; Gan, J; Gregory, JV; Jiménez, JA; Kadiyala, P; Lahann, J; Lawlor, ER; Lowenstein, PR; Martinez-Revollar, G; Mauser, A; McClellan, BL; Mujeeb, AA; Olin, MR; Schwendeman, A; Stamatovic, SM; Sun, Y; Taher, A; Thalla, R; Varela, ML | 1 |
| de Vries, EF; Dierckx, RA; Hartimath, SV; van Waarde, A | 1 |
| Esencay, M; Newcomb, EW; Zagzag, D | 1 |
| Bian, XW; Chen, JH; Cui, YH; Jiang, JY; Jiang, T; Lin, MC; Ping, YF; Qian, C; Wang, B; Wang, Jm; Yao, XH; Yu, SC; Zhang, R; Zhao, LT | 1 |
| Sarkar, S; Yong, VW; Zhang, J | 1 |
| Chan, JA; Kung, AL; Redjal, N; Segal, RA | 1 |
6 other study(ies) available for plerixafor and Glioma
| Article | Year |
|---|---|
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Glioblastoma; Glioma; Humans; Immunotherapy; Mice; Nanoparticles; Receptors, CXCR4; Signal Transduction; Tumor Microenvironment | 2022 |
Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model.
Topics: Animals; Benzylamines; Brain Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Cyclams; Gene Expression Regulation; Glioma; Heterocyclic Compounds; Humans; Ions; Ligands; Male; Microsomes, Liver; Neoplasm Metastasis; Neoplasm Transplantation; Positron-Emission Tomography; Pyridines; Rats; Rats, Wistar; Receptors, CXCR4 | 2014 |
HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration.
Topics: Benzylamines; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Drug Interactions; Gene Expression Regulation, Neoplastic; Glioma; Heterocyclic Compounds; Humans; Nerve Growth Factor; NF-kappa B; Receptors, CXCR4; RNA, Small Interfering; Time Factors; Transfection | 2010 |
The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.
Topics: AC133 Antigen; Animals; Antigens, CD; Benzylamines; Cell Transformation, Neoplastic; Chemokine CXCL12; Cyclams; Gene Knockdown Techniques; Glioma; Glycoproteins; Heterocyclic Compounds; Humans; Mice; Mice, SCID; Neoplasm Proteins; Neoplastic Stem Cells; Neovascularization, Pathologic; Peptides; Phosphatidylinositol 3-Kinases; Platelet Endothelial Cell Adhesion Molecule-1; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase.
Topics: Animals; Anti-HIV Agents; Benzylamines; Blotting, Western; Cell Proliferation; Chemokine CXCL12; Chemokines, CXC; Collagen; Cyclams; Drug Combinations; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Heterocyclic Compounds; Humans; Laminin; Matrix Metalloproteinase 15; Matrix Metalloproteinases, Membrane-Associated; Metalloendopeptidases; Mice; Mice, Nude; Neoplasm Invasiveness; Proteoglycans; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tumor Cells, Cultured | 2005 |
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Brain Neoplasms; Carmustine; Cell Proliferation; Cyclams; Drug Synergism; Glioblastoma; Glioma; Heterocyclic Compounds; Humans; Mice; Mice, Nude; Receptors, CXCR4; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |